Equities

Relmada Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Relmada Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.61
  • Today's Change-0.060 / -8.97%
  • Shares traded90.19k
  • 1 Year change-86.01%
  • Beta0.6621
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

  • Revenue in USD (TTM)0.00
  • Net income in USD-75.71m
  • Incorporated2012
  • Employees17.00
  • Location
    Relmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
  • Phone+1 (646) 876-3459
  • Websitehttps://www.relmada.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
RLMD:NSQ since
announced
Transaction
value
Asarina Pharma AB-Sepranolone GABAA NeurosteroidDeal completed06 Feb 202506 Feb 2025Deal completed60.53%--
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cocrystal Pharma Inc0.00-15.85m18.31m11.00--2.51-----1.56-1.560.000.71790.00----0.00-85.20-43.29-96.36-45.24-------4,873.78----0.00------2.67---43.98--
Plus Therapeutics Inc (USA)5.21m-27.12m18.34m21.00------3.52-2.51-2.510.5661-1.390.589----247,904.80-306.82-80.94---211.40-----520.90-605.55---0.911----18.54-3.612.54--59.47--
Cingulate Inc0.00-16.38m18.47m13.00--2.81-----10.21-10.210.001.550.00----0.00-182.32-157.80-324.15-303.36------------0.4598------33.95---26.92--
Reviva Pharmaceuticals Holdings Inc0.00-28.92m18.78m14.00---------0.8003-0.80030.00-0.09540.00----0.00-281.12--------------------------23.79------
NuCana PLC (ADR)0.00-19.75m19.16m20.00--0.0541-----7.41-7.410.000.92720.00----0.00-80.39-47.75-199.50-58.87------------0.0398------31.25---25.32--
Marker Therapeutics Inc5.70m-12.78m19.35m5.00--1.32--3.40-1.32-1.320.59761.290.3665--2.641,139,224.00-82.26-57.72-97.30-69.11-----224.45-761.28----0.00--99.0698.6323.60------
Linike Medical Group Ltd0.00-306.90k19.53m-----------0.1102-0.11020.00-0.1530.00-------278.62---------------------------651.26------
Goldenwell Biotech Inc140.00-134.91k19.80m--------141,428.60-0.0014-0.00140.00-0.00080.00070.0004-----69.03-95.49-69.57-110.1250.0052.18-96,364.29-2,064.279.21-11.85-----92.39-13.55-12.05------
Relmada Therapeutics Inc0.00-75.71m20.25m17.00--0.9023-----2.50-2.500.000.67610.00----0.00-135.09-77.37-160.24-84.69------------0.00------19.04------
Finch Therapeutics Group Inc0.00-14.17m20.47m18.00--1.44-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Apimeds Pharmaceuticals US Inc0.00-1.50m20.61m2.00---------0.1454-0.14540.00-0.22270.00----0.00-716.40-----------------10.67---------78.73------
Longeveron Inc2.23m-25.57m21.31m25.00--1.24--9.58-2.77-2.770.1781.150.1457--21.5089,000.00-110.81-70.26-150.26-83.9282.2944.57-760.63-683.81----0.00--237.38-15.76-10.86--51.32--
Mira Pharmaceuticals Inc0.00-7.92m21.66m----16.63-----0.5021-0.50210.000.0770.00-------304.03---355.82--------------0.00------34.46------
Curis Inc11.20m-42.13m21.96m33.00------1.96-6.23-6.231.60-0.63150.2211--5.01339,454.50-83.14-37.70-120.49-42.6399.4296.89-376.08-423.79--------8.831.758.49------
Chemomab Therapeutics Ltd - ADR0.00-13.40m22.16m16.00--2.10-----0.713-0.7130.000.5510.00----0.00-86.93---110.82--------------0.00------42.43------
Data as of Jul 11 2025. Currency figures normalised to Relmada Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

22.52%Per cent of shares held by top holders
HolderShares% Held
Squadron Capital Management LLCas of 24 Apr 20252.05m6.79%
Acadian Asset Management LLCas of 31 Mar 20251.23m4.07%
The Vanguard Group, Inc.as of 31 Mar 20251.20m3.97%
BlackRock Fund Advisorsas of 31 Mar 2025562.21k1.86%
Palo Alto Investors LPas of 31 Mar 2025495.15k1.64%
Geode Capital Management LLCas of 31 Mar 2025301.88k1.00%
Two Sigma Advisers LPas of 31 Mar 2025288.00k0.95%
AdvisorShares Investments LLCas of 31 Mar 2025276.51k0.92%
DWS Investments (UK) Ltd.as of 31 Mar 2025224.85k0.75%
Two Sigma Investments LPas of 31 Mar 2025170.54k0.57%
More ▼
Data from 31 Mar 2025 - 24 Apr 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.